Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
41.17
-0.03 (-0.07%)
At close: Apr 28, 2026, 4:00 PM EDT
41.15
-0.02 (-0.05%)
Pre-market: Apr 29, 2026, 5:14 AM EDT
Novo Nordisk Market Cap
Novo Nordisk has a market cap or net worth of $184.25 billion as of April 28, 2026. Its market cap has decreased by -36.25% in one year.
Market Cap
184.25B
Enterprise Value
200.54B
1-Year Change
-36.25%
Ranking
Category
Stock Price
$41.17
Market Cap Chart
Since December 1, 1998, Novo Nordisk's market cap has increased from $5.15B to $184.25B, an increase of 3,474.22%. That is a compound annual growth rate of 13.93%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 28, 2026 | 183.82B | -18.69% |
| Dec 31, 2025 | 226.09B | -41.72% |
| Dec 31, 2024 | 387.95B | -17.76% |
| Dec 29, 2023 | 471.73B | 54.12% |
| Dec 30, 2022 | 306.08B | 19.24% |
| Dec 31, 2021 | 256.69B | 55.86% |
| Dec 31, 2020 | 164.70B | 16.14% |
| Dec 31, 2019 | 141.81B | 23.12% |
| Dec 31, 2018 | 115.18B | -15.84% |
| Dec 29, 2017 | 136.86B | 46.79% |
| Dec 30, 2016 | 93.24B | -38.18% |
| Dec 31, 2015 | 150.82B | 29.59% |
| Dec 31, 2014 | 116.38B | 12.48% |
| Dec 31, 2013 | 103.47B | 9.30% |
| Dec 31, 2012 | 94.66B | 36.88% |
| Dec 30, 2011 | 69.16B | -0.91% |
| Dec 31, 2010 | 69.79B | 72.41% |
| Dec 31, 2009 | 40.48B | 26.82% |
| Dec 31, 2008 | 31.92B | -22.43% |
| Dec 31, 2007 | 41.15B | 52.03% |
| Dec 29, 2006 | 27.07B | 44.82% |
| Dec 30, 2005 | 18.69B | 1.87% |
| Dec 31, 2004 | 18.35B | 29.73% |
| Dec 31, 2003 | 14.14B | 41.73% |
| Dec 31, 2002 | 9.98B | 25.01% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 547.64B |
| AbbVie | 351.47B |
| AstraZeneca | 292.25B |
| Merck & Co. | 276.38B |
| Novartis AG | 276.01B |
| Amgen | 185.95B |
| Gilead Sciences | 161.86B |
| Pfizer | 153.59B |